Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Climb Bio Logo
Climb Bio Growth Score
77
CB Rank
5196
Heat Score
67
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Founded
obfuscation
PublicPost-IPO Equity Redmond, Washington, United States11-50 climbbio.com
Biotechnology
Health Care
Medical
Neuroscience
Pharmaceutical
Overview

Climb Bio
Total Funding
obfuscation
Growth Score
77
Heat Score
67

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score77
-2 pts
in past quarter
Heat Score 67
18 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Climb Bio

CB Rank
5196
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Founded
obfuscation
PublicPost-IPO Equity Redmond, Washington, United States11-50 climbbio.com
Biotechnology
Health Care
Medical
Neuroscience
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series B
OBF
in
obfuscation

Key People

  • Bob Azelby Logo
    Bob Azelby: President and Chief Executive Officer
  • Photo of Edgar Charles
    Edgar Charles: Chief Medical Officer
    Past Role: Bristol-Myers Squibb, Vice President and Senior Global Program Lead for Immunology

Details

Legal Name Climb Bio
Also Known As Eliem Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:CLYM
Company Type For Profit
Founders  Andrew Levin, David-Alexandre Gros, Valerie Morisset
About the Company
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Phone Number +1 866 857 2596
Contact Email media@eliemtx.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Climb Bio is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

ETX-155
An investigational oral neuroactive steroid GABAA receptor positive allosteric modulator for major depressive disorder and focal onset seizures.
Budoprutug IV Anti-CD19 Monoclonal Antibody
An intravenous anti-CD19 monoclonal antibody candidate targeting B-cell mediated immune diseases such as membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

Research & Development

Climb Bio is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
11
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Cormorant Asset Management Logo
Cormorant Asset Management
—
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
—
Cormorant Asset Management Logo
Cormorant Asset Management
—
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
—
Cormorant Asset Management Logo
Cormorant Asset Management
—
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
—
Cormorant Asset Management Logo
Cormorant Asset Management
—
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
—
Cormorant Asset Management Logo
Cormorant Asset Management
—
Post-IPO Equity - Climb Bio Logo
Post-IPO Equity - Climb Bio
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 11 Board Members and Advisors 6 Contacts 7

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,882
-48.03%
 in past month

IT Spend

$1.5MThis year, Climb Bio is projected to spend $1.5M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
LinkedIn Logo
LinkedIn
87
Research and Development / Test Logo
Research and Development / Test
83
AWS NAT Gateway Logo
AWS NAT Gateway
82

Active Website Tech Count

19Climb Bio is actively using 19 technologies for its website, according to BuiltWith. These include Viewport Meta, Common Crawl, and  IPhone / Mobile Compatible.
Sub-Organizations
Frequently Asked Questions

Where is Climb Bio's headquarters? Climb Bio is located in Redmond, Washington, United States.Who invested in Climb Bio? Climb Bio has 21 investors including Cormorant Asset Management and  Affinity Asset Advisors.When was the last funding round for Climb Bio? Climb Bio closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Climb Bio's competitors? Alternatives and possible competitors to Climb Bio may include Takeda, Amgen, and  Alto Neuroscience.How much funding has Climb Bio raised to date? Climb Bio has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(6ec160d 1)
|